Come join others currently navigating treatment in our weekly Zoom Meetup! Register here: Tuesdays, 1pm ET.
Join us October 17 for our Webinar: Beyond Treatment: Getting the Follow Up Care You Need Register here.

New BCO Content on Recently Approved Immunotherapy Jemperli

Jemperli (chemical name: dostarlimab-gxly) is approved by the U.S. Food and Drug Administration (FDA) to treat mismatch repair deficient (dMMR) advanced-stage breast cancer that has grown during or after treatment if no other treatment options are available.

Jemperli also is approved to treat dMMR advanced-stage endometrial cancer that has grown after treatment with platinum chemotherapy.

Learn more about:

Read more.